Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) closed the day trading at $6.44 down -1.08% from the previous closing price of $6.51. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 0.58 million shares were traded. BCYC stock price reached its highest trading level at $6.5433 during the session, while it also had its lowest trading level at $6.19.
Ratios:
For a better understanding of BCYC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.66 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 08, 2024, Stephens started tracking the stock assigning a Equal-Weight rating and target price of $25.
On September 06, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $35.RBC Capital Mkts initiated its Outperform rating on September 06, 2024, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 03 ’25 when Lee Kevin sold 3,231 shares for $8.41 per share. The transaction valued at 27,173 led to the insider holds 475,310 shares of the business.
Lee Kevin sold 2,263 shares of BCYC for $19,009 on Oct 02 ’25. The CHIEF EXECUTIVE OFFICER now owns 478,541 shares after completing the transaction at $8.40 per share. On Oct 03 ’25, another insider, Skynner Michael, who serves as the CHIEF TECHNOLOGY OFFICER of the company, sold 978 shares for $8.41 each. As a result, the insider received 8,225 and left with 118,277 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCYC now has a Market Capitalization of 446729248 and an Enterprise Value of -195852752. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.34 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at -6.911 whereas that against EBITDA is 0.691.
Stock Price History:
The Beta on a monthly basis for BCYC is 1.51, which has changed by -0.73519737 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, BCYC has reached a high of $25.39, while it has fallen to a 52-week low of $6.10. The 50-Day Moving Average of the stock is -15.42%, while the 200-Day Moving Average is calculated to be -24.61%.
Shares Statistics:
Over the past 3-months, BCYC traded about 298.17K shares per day on average, while over the past 10 days, BCYC traded about 418890 shares per day. A total of 49.87M shares are outstanding, with a floating share count of 44.08M. Insiders hold about 11.60% of the company’s shares, while institutions hold 69.99% stake in the company. Shares short for BCYC as of 1760486400 were 1536480 with a Short Ratio of 5.15, compared to 1757894400 on 1461486. Therefore, it implies a Short% of Shares Outstanding of 1536480 and a Short% of Float of 4.0.
Earnings Estimates
The stock of Bicycle Therapeutics Plc ADR (BCYC) is currently drawing attention from 9.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.64 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$3.66 and -$4.4 for the fiscal current year, implying an average EPS of -$3.88. EPS for the following year is -$3.61, with 8.0 analysts recommending between -$2.44 and -$4.39.
Revenue Estimates
11 analysts predict $7.31M in revenue for. The current quarter. It ranges from a high estimate of $15M to a low estimate of $2.92M. As of. The current estimate, Bicycle Therapeutics Plc ADR’s year-ago sales were $3.71MFor the next quarter, 11 analysts are estimating revenue of $7.25M. There is a high estimate of $10.48M for the next quarter, whereas the lowest estimate is $2.9M.
A total of 12 analysts have provided revenue estimates for BCYC’s current fiscal year. The highest revenue estimate was $39.63M, while the lowest revenue estimate was $27.55M, resulting in an average revenue estimate of $32.45M. In the same quarter a year ago, actual revenue was $35.27MBased on 13 analysts’ estimates, the company’s revenue will be $33.85M in the next fiscal year. The high estimate is $60M and the low estimate is $11.68M.
